Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Bought by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. grew its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 39.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 112,400 shares of the company's stock after buying an additional 31,800 shares during the quarter. Jefferies Financial Group Inc. owned 0.16% of Kiniksa Pharmaceuticals worth $2,223,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the business. SG Americas Securities LLC bought a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $355,000. China Universal Asset Management Co. Ltd. boosted its holdings in Kiniksa Pharmaceuticals by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after acquiring an additional 1,004 shares in the last quarter. Peregrine Capital Management LLC lifted its stake in shares of Kiniksa Pharmaceuticals by 1.8% during the fourth quarter. Peregrine Capital Management LLC now owns 244,043 shares of the company's stock worth $4,827,000 after buying an additional 4,361 shares during the period. New York State Common Retirement Fund lifted its position in Kiniksa Pharmaceuticals by 12.4% during the 4th quarter. New York State Common Retirement Fund now owns 15,248 shares of the company's stock worth $302,000 after acquiring an additional 1,680 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Kiniksa Pharmaceuticals during the 4th quarter valued at approximately $258,000. Institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Price Performance

Shares of KNSA stock traded up $0.25 during trading on Friday, reaching $27.43. The company's stock had a trading volume of 543,644 shares, compared to its average volume of 492,080. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $17.38 and a 1-year high of $28.56. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of -195.91 and a beta of 0.07. The stock's 50-day moving average price is $23.62 and its 200 day moving average price is $21.63.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.09. The firm had revenue of $137.79 million during the quarter, compared to analysts' expectations of $128.35 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business's revenue was up 72.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.25) EPS. On average, sell-side analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

KNSA has been the subject of a number of analyst reports. Citigroup began coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a "buy" rating and a $40.00 price target for the company. Jefferies Financial Group increased their target price on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $38.80.

Insider Buying and Selling

In related news, COO Eben Tessari sold 12,000 shares of the stock in a transaction on Monday, April 14th. The stock was sold at an average price of $20.48, for a total transaction of $245,760.00. Following the completion of the sale, the chief operating officer now directly owns 77,363 shares of the company's stock, valued at $1,584,394.24. This trade represents a 13.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Ross Moat sold 18,259 shares of the firm's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $20.29, for a total transaction of $370,475.11. Following the completion of the sale, the insider now owns 9,415 shares of the company's stock, valued at $191,030.35. This trade represents a 65.98% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 329,910 shares of company stock worth $8,336,038 in the last 90 days. Company insiders own 54.57% of the company's stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.